US Patent 9,643,929: Eslicarbazepine Acetate Purity Claims, Scope, Expiration and Generic Risk
US Patent 9,643,929 protects pharmaceutical compositions containing high-purity eslicarbazepine acetate, the active ingredient in Aptiom. Its central limitation is chemical purity of at least approximately 99.96%, with dependent protection for compositions in which the opposite, R-enantiomer is below the limit of detection. The patent does not broadly cover every eslicarbazepine acetate product, every dosage form, or the compound itself without the claimed purity threshold.
What drug does US Patent 9,643,929 protect?
The claimed compound is (S)-(−)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide, commonly known as eslicarbazepine acetate.
| Item |
Analysis |
| Active ingredient |
Eslicarbazepine acetate |
| Brand product |
Aptiom |
| Sponsor historically associated with US commercialization |
Sunovion Pharmaceuticals |
| Original developer and patent holder associated with the eslicarbazepine acetate program |
BIAL-Portela & C.A., S.A. |
| Therapeutic area |
Partial-onset seizures in epilepsy |
| FDA dosage form |
Oral tablets |
| Patent at issue |
US 9,643,929 |
| Patent title |
Pharmaceutical compositions comprising eslicarbazepine acetate |
| Issue date |
May 9, 2017 |
| Core protection |
Composition containing eslicarbazepine acetate at at least approximately 99.96% chemical purity |
| Additional protection |
R-isomer below the limit of detection |
The FDA approved Aptiom in November 2013 for the treatment of partial-onset seizures in patients four years of age and older. The product is a small-molecule drug, so biosimilar regulation under the Public Health Service Act is not relevant. Generic applicants use the abbreviated new drug application, or ANDA, pathway instead. (U.S. Food and Drug Administration, 2013)
What do the claims of US Patent 9,643,929 cover?
Claim 1: open composition claim
Claim 1 covers:
A pharmaceutical composition comprising eslicarbazepine acetate having a chemical purity of at least about 99.96%.
The term “comprising” makes the claim open-ended. A product can contain additional ingredients and still fall within the claim if it contains the specified high-purity eslicarbazepine acetate.
The claim does not specify:
- A tablet, capsule, suspension, or other dosage form
- A particular excipient
- A specific eslicarbazepine acetate dose
- A release profile
- A crystalline form or polymorph
- A manufacturing process
- A particular therapeutic indication
- A particular impurity profile other than the purity threshold
The claim therefore has broad composition coverage, but only for products meeting the purity limitation.
Claim 2: active pharmaceutical ingredient limitation
Claim 2 covers a pharmaceutical composition in which the active pharmaceutical ingredient consists of eslicarbazepine acetate having at least approximately 99.96% chemical purity.
This claim is narrower than claim 1 in one respect. The phrase “active pharmaceutical ingredient consisting of” limits the API identity to the specified eslicarbazepine acetate. It does not necessarily exclude conventional inactive excipients from the finished pharmaceutical composition.
The practical distinction is important. A finished tablet containing eslicarbazepine acetate, binders, lubricants and disintegrants can still satisfy claim 2 if the API itself consists of the claimed high-purity material.
Claim 3: R-isomer below the detection limit
Claim 3 depends on claim 2 and requires the amount of the R-isomer to be below the limit of detection.
This creates two cumulative requirements:
- The eslicarbazepine acetate API has chemical purity of at least approximately 99.96%.
- The R-enantiomer is below the applicable analytical detection limit.
Claim 3 is narrower than claims 1 and 2. A product can satisfy the 99.96% purity requirement but avoid claim 3 if the R-isomer is detectable, even in a very small amount.
What is the key patent-law issue in these claims?
The principal issue is whether the accused product meets the purity limitation. The claims are composition claims, not process claims. A generic manufacturer could use a different synthesis route and still infringe if the resulting API is incorporated into a pharmaceutical composition that satisfies the claimed purity requirements.
The critical evidence would normally include:
- Certificate-of-analysis data
- Chiral purity testing
- Achiral impurity testing
- Validation of the analytical method
- Detection and quantitation limits
- Batch records
- Stability data
- API specifications
- Finished-product composition
- Regulatory filings describing the API
A generic label alone may not establish every limitation of a composition claim. For an ANDA case, however, the proposed product, API specifications and manufacturing information can provide the basis for an infringement allegation under 35 U.S.C. § 271(e)(2).
How should “chemical purity of at least about 99.96%” be interpreted?
The purity limitation is the central vulnerability and enforcement point.
“About 99.96%” introduces a tolerance question. The permissible range depends on the patent specification, prosecution history, analytical method and how a court construes the term. The claim does not state whether chemical purity is measured by:
- High-performance liquid chromatography
- Area percent or weight percent
- Assay of the desired enantiomer
- Total organic impurities
- A named pharmacopeial method
- A particular reference standard
Chemical purity and enantiomeric purity are related but distinct. A product may have high total chemical purity while containing measurable R-eslicarbazepine acetate. Conversely, a product may have very high enantiomeric purity but contain non-chiral chemical impurities.
Claim 3 addresses the R-isomer separately. That separation suggests the patent treats total chemical purity and R-isomer control as distinct analytical characteristics.
What is the likely infringement theory against a generic eslicarbazepine acetate product?
A patent owner would likely argue that an ANDA product infringes when:
- The proposed product contains eslicarbazepine acetate.
- The API has at least approximately 99.96% chemical purity.
- The product is a pharmaceutical composition.
- For claim 3, the R-isomer is below the specified detection limit.
The generic applicant could challenge infringement by arguing that:
- The API purity is below the claim threshold.
- The product does not satisfy the meaning of “about 99.96%.”
- The analytical method does not demonstrate the required purity.
- The R-isomer is detectable.
- The claim is indefinite because the detection limit is not sufficiently defined.
- The product contains an impurity profile outside the claim.
- The claim is invalid for lack of written description or enablement.
The strongest design-around strategy would generally require a product that falls outside the claimed purity or R-isomer parameters. Changing excipients alone would likely be ineffective because the claims do not require a specific excipient system.
When does US Patent 9,643,929 lose exclusivity?
The patent has a nominal 20-year term measured from the applicable nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers and any other statutory modification. Public patent records associate the patent family with a 2011 priority date and an expected US term extending into approximately 2032. The exact controlling expiration date should be taken from the current USPTO patent record and FDA Orange Book listing rather than inferred from the issue date. (U.S. Patent and Trademark Office, 2017)
The patent is therefore a later-expiring layer in the Aptiom estate compared with earlier compound and method patents. Its commercial value comes from potentially extending protection for high-purity API products after earlier broad patents expire.
FDA regulatory exclusivity
Aptiom’s regulatory exclusivity is separate from patent protection.
| Exclusivity type |
Relevance |
| New chemical entity exclusivity |
Applied to the original FDA approval period |
| Pediatric exclusivity |
May add six months if granted for completed FDA-requested studies |
| Orphan exclusivity |
Not the principal exclusivity mechanism for Aptiom |
| Patent exclusivity |
Depends on the surviving patent claims and listed expiration dates |
| Biosimilar exclusivity |
Not applicable |
| ANDA approval |
Available after regulatory and patent barriers are satisfied |
FDA exclusivity does not extend the patent term. Conversely, an unexpired patent may delay or restrict generic launch after FDA regulatory exclusivity has ended.
What other patents protect eslicarbazepine acetate and Aptiom?
The broader Aptiom patent estate has historically included multiple categories:
| Patent category |
Typical subject matter |
Relevance to US 9,643,929 |
| Compound patents |
Eslicarbazepine acetate and related chemical entities |
Broader chemical protection, usually earlier-expiring |
| Stereochemical patents |
S-isomer, R-isomer or stereoselective compositions |
Overlaps with the purity and enantiomer limitations |
| Pharmaceutical composition patents |
API with excipients or defined purity |
Closest category to US 9,643,929 |
| Method-of-use patents |
Treatment of epilepsy and partial-onset seizures |
Can create separate ANDA litigation exposure |
| Manufacturing patents |
Resolution, synthesis, purification or crystallization |
Can create process and supply-chain barriers |
| Formulation patents |
Tablets, dosage strengths, release profiles or excipient systems |
Relevant only if the generic product practices those limitations |
US 9,643,929 is materially narrower than a patent claiming eslicarbazepine acetate as a chemical entity. Its value depends on whether commercial API production routinely reaches the claimed purity threshold. Modern pharmaceutical API processes may naturally produce material above 99.96%, which can make a purity claim commercially significant even when the claim appears narrow on its face.
What formulations are protected by US 9,643,929?
The patent claims a pharmaceutical composition but does not, based on the quoted claims, require a particular formulation.
Potentially covered products may include:
- Immediate-release tablets
- Capsules
- Oral powders
- Granules
- Suspensions
- Other pharmaceutical compositions containing the qualifying API
The claims do not expressly require Aptiom’s marketed tablet strengths or excipient combination. A generic tablet could therefore fall within the claims even if it uses different inactive ingredients, provided the API and purity limitations are met.
A formulation patent would normally require additional limitations such as a defined dosage strength, dissolution profile, particle-size distribution, excipient ratio or release mechanism. Those limitations are absent from the quoted claims.
Is US 9,643,929 a method-of-use patent?
No. The quoted claims are composition claims.
They do not require:
- Treating epilepsy
- Treating partial-onset seizures
- Administering a particular dose
- Administering the drug on a specified schedule
- Treating a defined patient population
This distinction affects ANDA strategy. A generic applicant may use a section viii “skinny label” approach for a valid, unexpired method-of-use patent where the patented indication can be carved out. That strategy does not eliminate a composition patent directed to the generic product itself.
What is the Paragraph IV risk?
A generic applicant seeking approval before expiration would need to address the listed patents through a Paragraph IV certification, a section viii statement where applicable, or another statutory pathway.
For US 9,643,929, a Paragraph IV challenge could assert:
- Non-infringement because purity is below the claimed level
- Non-infringement because the R-isomer is detectable
- Invalidity for indefiniteness
- Invalidity for lack of written description
- Invalidity for lack of enablement
- Obviousness based on prior high-purity eslicarbazepine acetate compositions
- Failure to satisfy the statutory requirements for a patentable composition
A Paragraph IV notice can trigger a Hatch-Waxman action within 45 days and a potential 30-month stay of FDA approval, subject to statutory exceptions. The economic impact depends on the number of ANDA filers, the listed patent status, settlement terms and whether the challenged patent survives early case resolution.
Which companies are challenging Aptiom patents?
The claim text does not identify generic applicants, Paragraph IV filers, litigation defendants or settlement counterparties. Those facts are not established by US Patent 9,643,929 itself.
A complete challenge analysis requires matching the patent against:
- Current Orange Book listings
- FDA Paragraph IV notices
- District court complaints
- ANDA litigation dockets
- Patent settlements
- Generic approval records
The patent number alone does not prove that a specific company has challenged, settled or launched around the patent.
Does biosimilar risk apply to eslicarbazepine acetate?
No. Eslicarbazepine acetate is a synthetic small-molecule active ingredient. The relevant competitive threat is generic substitution through ANDAs, not biosimilar approval under section 351(k) of the Public Health Service Act.
Generic risk is likely to focus on:
- Purity specifications
- Enantiomeric control
- Label carve-outs
- Formulation differences
- API sourcing
- Manufacturing process patents
- Market exclusivity and settlement dates
How strong is the patent estate for Aptiom?
US 9,643,929 is strongest where commercial API specifications routinely exceed 99.96% and where the R-isomer is consistently below the analytical detection limit. It is weaker if:
- The specification does not clearly define the analytical method
- The prosecution history narrowed the claim
- The purity threshold lacks reproducible measurement
- Prior art disclosed highly pure eslicarbazepine acetate
- Generic products can be manufactured below the threshold without compromising regulatory quality
- The patent is not listed for the relevant product or has been disclaimed
The patent is not a complete substitute for broad compound, method-of-use, formulation and manufacturing patents. It is one layer of a broader exclusivity strategy.
What is the commercial impact of generic entry?
Aptiom revenue is exposed to generic entry when the surviving patent and regulatory barriers no longer prevent ANDA approval. The commercial effect is likely to be substantial because oral antiepileptic drugs are generally vulnerable to rapid price erosion after multiple generic launches.
The high-purity composition claim can delay or complicate entry if generic products must meet the claimed specification. It may have less practical force if:
- The listed patent expires before meaningful market entry
- A generic applicant obtains a court ruling of invalidity or non-infringement
- A settlement permits an authorized or licensed generic
- Several generic manufacturers launch after an agreed date
- The FDA determines that the patent does not block approval
Key Takeaways
- US 9,643,929 is a high-purity composition patent for eslicarbazepine acetate.
- Claim 1 requires at least approximately 99.96% chemical purity and uses open “comprising” language.
- Claim 2 focuses on the API itself and retains the same purity threshold.
- Claim 3 adds the requirement that the R-isomer be below the limit of detection.
- The patent does not require a specific dose, tablet strength, excipient, polymorph, indication or manufacturing process.
- Infringement will turn primarily on API testing, analytical methodology and the meaning of “about 99.96%.”
- The patent is distinct from method-of-use and formulation patents.
- Eslicarbazepine acetate faces generic, not biosimilar, competition.
- The patent’s expected term extends into approximately 2032, subject to the controlling USPTO and Orange Book records.
- The quoted claims do not establish current Paragraph IV challengers, litigation defendants or settlement terms.
FAQs
Can a generic avoid US 9,643,929 by using different excipients?
Probably not if its API meets the claimed purity limitations. The claims do not require a specific excipient system, so changing inactive ingredients would not by itself avoid infringement.
Does 99.96% purity mean 99.96% S-isomer purity?
Not necessarily. The claim uses chemical purity language, while claim 3 separately addresses the R-isomer. The applicable specification and analytical method determine how the terms operate together.
Can a generic launch with detectable R-eslicarbazepine acetate?
A detectable R-isomer could provide a non-infringement position against claim 3, but it would not automatically avoid claims 1 or 2. Those claims do not expressly require the R-isomer to be below detection.
Is US 9,643,929 a patent on Aptiom’s tablet formulation?
Not specifically. The quoted claims cover pharmaceutical compositions containing qualifying high-purity eslicarbazepine acetate, without requiring Aptiom’s exact excipients, strength or dissolution profile.
What patent challenge would be most credible against US 9,643,929?
The principal challenges would focus on the scope and measurement of the 99.96% threshold, the meaning of “about,” the analytical definition of the limit of detection, and whether prior art disclosed or rendered obvious eslicarbazepine acetate at the claimed purity.
References
- U.S. Food and Drug Administration. (2013). Aptiom (eslicarbazepine acetate) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,643,929, Pharmaceutical compositions comprising eslicarbazepine acetate.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certifications.
- U.S. Code. (2024). 35 U.S.C. §§ 154, 271(e), and 282.
